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Sulpiride is an antipsychotic human drug. It is commonly used to encourage ovulation in
noncycling mares and to stimulate lactation in adoptive mares. No pharmacokinetic data
are available for donkeys. The aim of this study was to assess the pharmacokinetics proﬁle
of sulpiride after intravenous (IV), intramuscular (IM), and oral (PO) administrations in
healthy jennies. Animals (n ¼ 6) were treated with sulpiride, 1 mg/kg by IV, IM, and PO
routes according to a randomized cross-over design (3  3 Latin square). Blood samples
(5 mL) were collected at predetermined times and analyzed using a validated high per-
formance liquid chromatography with ﬂuorescence detection method. IV and IM admin-
istrations gave similar curves, but they were not bioequivalent. The IM average
bioavailability was 73.5%. After PO administration, the drug plasma concentrations were
low and consequently both area under the curve and bioavailability (9.4%) were low. This
ﬁnding could be because of the physicochemical features of the drug. Indeed, considering
that sulpiride is a weak base, existing in the ionized form at gastric and physiological pH, it
is unsurprising that it is poorly absorbable, especially in equine species whose gastric pH is
particularly acidic. In conclusion, injective routes are deﬁnitely preferable to PO dosing
because of the very low F% via this route.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Sulpiride (SLP) belongs to a special class of antipsy-
chotic drugs, the substituted benzamides. These possess a
more speciﬁc pharmacologic proﬁle than the conven-
tional neuroleptics. SLP selectively blocks the peripheral
and central dopamine (D2 subtype) receptors, whereas
the interaction with the D1 subtype is negligible. Prob-
ably, SLP does not interact with noradrenergic oremD, Department of
se (lato monte), San
. All rights reserved.serotonergic receptor mechanisms. Sulpiride is widely
used in humans as a behavior regulator to treat mental
disorders and for the psychopathology of senescence,
depression, and schizophrenia. The daily dose for these
indications is 200–800 mg [1]. It is also used at doses of
50–150 mg per human for the treatment of gastric or
duodenal ulcers [2], in the treatment of an irritable colon
due to psychosomatic stress [3], and in various vertigo
syndromes [4]. Tolerance to SLP at this lower dosage is
very good, and extrapyramidal, neurovegetative, and
endocrine side effects are rare [5].
The earliest application of this molecule in equine
reproduction was to treat fescue toxicosis (3.3 mg/kg): in
this application, a stimulation of endogenous prolactin
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was observed [6]. In subsequent studies, SLP has been used
to induce lactation in cycling and noncycling mares (0.5–
1 mg/kg twice a day) [7] or to hasten the ﬁrst ovulation of
the breeding season in noncycling mares (1 mg/kg once a
day) [8–11].
Although the effectiveness of SLP in transitional mares is
still controversial [8,11], SLP is used in equine practice.
Recently, a pharmacokinetic (PK) study has described its
disposition in horses [12]. Determining a rational dosing
regimen is a long and complicated endeavor because of
differences in the expression of enzymes, receptors, and
signal transduction molecules between species. Both inter-
and intra-species differences in drug response can be
accounted for as either being because of variations in drug
PK or drug pharmacodynamics; the magnitude and relative
contribution of each of these varies from drug to drug. In
addition, although animal species may be morphologically
similar, they can still have considerable differences in their
response to drugs. Optimization of treatment with SLP
initially requires knowledge of its bioavailability, PK, and
metabolism in the target species. The PK parameters
determined after a single-dose administration can then be
used for dosage regimen adjustments and individualization
of therapy. In addition, donkey might be of particular in-
terest because of its milk. Indeed, the global market is
asking for an increased production of donkey milk for its
excellent nutritive features [13]. Hence, the aim of this
study was to assess the PK proﬁle of SLP after intravenous
(IV), intramuscular (IM), and oral (PO) administrations in
healthy jennies.
2. Materials and Methods
2.1. Animal Treatments and Sampling
Six nurse jennies, aged 7–12 years and weighing 190–
250 kg, were used. The jennies were previously determined
to be clinically healthy based on a physical examination and
full chemistry and hematological analyses. Animal experi-
ments were conducted at the Veterinary Teaching Hospital,
School of Biosciences and Veterinary Medicine (University
of Camerino). Animal care and handling were performed
according to the provision of the EC council Directive 86/
609 EEC. The study protocol was approved by the Univer-
sity of Camerino’s Ethics Committee for animal welfare and
transmitted to the Italian Ministry of Health (authorization
number 11/2014). Animals were randomly assigned to
three treatment groups, using an open, single-dose, three-
treatment, three-period, paired, randomized cross-over
design (3  3 Latin square). Each subject in group I (n ¼
2) received a single dose of 1 mg/kg of SLP (Championyl,
Sanoﬁ Aventis, France) injected IV over 1 minute into the
left jugular vein, in the morning after fasting for 12 hours
overnight. Animals in group II (n ¼ 2) received the same
dose but by IM route, injected in themiddle quadrant of the
neck muscle, after fasting for 12 hours overnight. Animals
in group III (n ¼ 2), after overnight fasting, received the
same dose via nasogastric tube. For this route, tablets of SLP
were used (Championyl 50 mg/tablet Sanoﬁ Aventis). After
administration, the nasogastric tube was rinsed with300mL of distilled water to ensure complete delivery of the
drug into the stomach. A catheter was placed into the right
jugular vein to facilitate blood sampling. The washout
period was 1 week. The groups were rotated and the ad-
ministrations repeated. After 3 weeks, each donkey had
been administered with SLP by the three routes. Blood
samples (5 mL) were collected at 0, 5, 15, 30, and 45 mi-
nutes and 1, 1.5, 2, 4, 6, 8, 10, 24, and 34 hours after
administration of SLP and placed in collection tubes con-
taining lithium heparin. The blood samples were centri-
fuged at 3,000  gwithin 30 minutes of collection, and the
harvested plasma was stored at 20C until use within
30 days of collection.
2.2. Chemicals and Reagents
Pure powders of SLP (>99.0% purity) and metoclopra-
mide (internal standard [IS]) were sourced from
Sigma-Aldrich (St. Louis, MO). High performance liquid
chromatography (HPLC) grade acetonitrile (ACN), ethyl
acetate (EtAc), methanol (MeOH), and methylene chloride
(CH2Cl2) were purchased from Merck (Darmstadt, Ger-
many). Analytical grade sodium hydroxide (NaOH), acetic
acid (AcOH), and ammonium acetate (AcONH4) were pur-
chased from Carlo Erba (Milan, Italy). Deionized water was
produced by a Milli-Q Millipore Water System (Millipore,
MA). All the other reagents andmaterials were of analytical
grade and supplied from commercial sources. The aqueous
and organic components of the mobile phase, degassed
under pressure, were mixed by the HPLC. The liquid chro-
matography mobile phases were ﬁltered through 0.2-mm
cellulose acetate membrane ﬁlters (Sartorius Stedim
Biotech, Aubagne Cedex) with a solvent ﬁltration
apparatus.
2.3. Preparation of Solutions
Singular stock solutions of SLP and IS in MeOH were
prepared at an individual concentration of 1,000 mg/mL
using volumetric ﬂasks; these were stored at 20C. To
reach a ﬁnal concentration of 100 mg/mL, appropriate di-
lutions of stock standard solutions were prepared, diluting
1mL of each solution to 10mL. Successively, these solutions
of SLP and IS were diluted in glass tubes (10 mL) to reach
ﬁnal concentrations of 10, 5, and 1 mg/mL. These were
stored at 20C. This latter concentration (1 mg/mL) was
then diluted with MeOH to prepare a ﬁve-point calibration
curve of the analytes at the following concentrations:
0.200, 0.100, 0.050, 0.025, 0.010, and 0.001 mg/mL. The two
analytes were stable for at least 30 weeks if stored at
20C.
2.4. Instrumentation and Chromatographic Conditions
The HPLC system was an LC system (Jasco, Japan) con-
sisting of a high pressure mixer pump (model PU 980 Plus),
spectroﬂuorometric detector (model 2020 Plus), and a loop
of 50 mL. Data were processed by Borwin software (Jasco,
Inc.). Chromatographic separation assay was performed by
a Luna C18 ODS2 analytical column (150  4.6 mm inner
diameter, 5-mm particle size, Phenomenex, Torrance, CA)
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buffer (10 mM AcONH4, adjusted to pH 5.2 with AcOH;
15:85 vol/vol%) at a ﬂow rate of 1.2 mL/min. Excitation and
emission wavelengths were set at 300 and 356 nm,
respectively.2.5. Sample Extraction
The procedure was based on a previously reported
method [12]. Brieﬂy, in a 15-mL screw cap polypropylene
vial, a 1-mL aliquot of plasma sample was added to 100 mL
of IS (0.25 mg/mL). After 30-second vortexing, 0.1 mL of
NaOH (1 M) was added and the sample vortexed again. An
aliquot of 6 mL of EtAc:CH2Cl2 (5:1, vol/vol) was added,
then vortexed (30 seconds), shaken (60 osc/min, 10 mi-
nutes) and centrifuged at 10,956 g for 10 minutes at 10C.
The supernatant was collected in a new 15-mL screw cap
vial. The organic phase was evaporated under a gentle
stream of nitrogen (40C) and reconstituted with 200 mL of
mobile phase. Fifty microliters of this solution was injected
onto the HPLC with ﬂuorescence detector.2.6. Quantiﬁcation
The calibration curve of peak area versus concentration
(ng/mL) of SLP was plotted. Least squares regression pa-
rameters for the calibration curve were calculated, and the
concentrations of the test samples were interpolated from
the regression parameters. Sample concentrations were
determined by linear regression, using the formula Y ¼mX
þ b, where Y¼peak area, X¼ concentration of the standard
in ng/mL, m ¼ the slope of the curve, and b ¼ the intercept
with Y axis. Correlation coefﬁcients for each of the cali-
bration curves were >0.99.
When unknown samples were assayed, a control and a
fortiﬁed blank sample were processed simultaneously for
quality control. Limit of detection (LOD) and limit of
quantiﬁcation (LOQ) were determined as analyte concen-
trations giving signal-to-noise ratios of 3 and 10, respec-
tively. Limit of quantiﬁcation was 1 ng/mL, and LOD wasTable 1
Main (two-compartment model) pharmacokinetic parameters of sulpiride (SLP) a
SLP (1 mg/kg) in jennies.
Parameters IV (n ¼ 6)
R2 0.99  0.01
AUC0–N (ng hr/mL) 7,935.03  1,127.20
CL (mL/hr/kg) 133.81  37.62
VD (mL/kg) 410.46  93.47
HL alpha (hr) 0.24  0.09
HL beta (hr) 4.24  0.84
K10 (1/hr) 1.03  0.22
K12 (1/hr) 1.78  0.88
K21 (1/hr) 0.65  0.21
K01 (1/hr)
Tmax (hr)
Cmax (ng/mL)
F%
Abbreviations: AUC0–N, area under the plasma concentration–time curve extra
absolute bioavailability; HL alpha, distribution half-life; HL beta, disposition ha
distribution in peripheral tissues rate constant; K21, transfer rate constant from tis
distribution.5 ng/mL. The values of precision for SLP were always lower
or equal to 5.4 (coefﬁcient of variability%), whereas accu-
racy was less than 6.3%.2.7. PK Analysis
The PK calculations were carried out using WinNonLin
version 5.3.1 (Pharsight Corp). The exponential parameters,
in addition to the error model parameters, were estimated
[14]. Sulpiride plasma concentrations versus time curves
were modeled for each subject using a monocompartment
or a two-compartment open model. Comparison between
competing models was made using the Akaike test.
Maximum concentration (Cmax) of SLP in plasma and the
time required to reach Cmax (Tmax) were predicted from the
data. The area under the concentration versus time curve
(AUC0–N) was calculated using the linear trapezoidal rule.
Intramuscular or PO bioavailability (F%) was calculated
from the ratio of the areas under the plasma SLP concen-
tration curve after IM, PO, and IV administrations, indexed
to their respective dose:
Fð%Þ ¼ ðAUCIM or PO DoseIVÞ ðAUCIV DoseIM or POÞ  100=
The compartmental PK variables absorption rate (K01),
elimination rate from compartment 1 (K10), rate of move-
ment from compartment 1 to 2 (K12), the rate of movement
from compartment 2 to 1 (K21), half-life of distribution
phase (HL alpha), half-life of the elimination phase (HL
beta), clearance (CL), and volume of distribution (VD) are
presented in Table 1.2.8. Statistical Analysis
To make comparisons across treatments, the different
parameters were ﬁrst tested for normal distribution and
variance homogeneity. This was achieved by performing a
two-way analysis of variance on the randomized 3 x 3 Latin
square design.fter intravenous (IV), intramuscular (IM), and oral (PO) administrations of
IM (n ¼ 5) PO (n ¼ 4)
0.99  0.01 0.97  0.03
6,263.54  946.40 617.89  48.04
165.77  33.05 1,618.41  68.63
411.95  86.36 87.10  14.89
0.40  0.23 0.96  0.01
3.87  0.85 2.89  0.95
0.45  0.23 0.71  0.01
1.35  0.56 0.01  0.003
1.04  0.27 0.24  0.04
8.12  1.36 0.75  0.01
0.32  0.09 1.37  0.47
1,534.55  68.11 164.55  22.92
73.5  7.2 9.4  5.9
polated to inﬁnity; CL, clearance; Cmax, peak plasma concentration; F%,
lf-life; K01, absorption rate constant; K10, elimination rate constant; K12,
sue to plasma; R2, correlation coefﬁcient; Tmax, time of peak; VD, volume of
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Fig. 1. Observed mean plasma concentrations of sulpiride (SLP) after IV
(–B–, n ¼ 6), IM (–:–, n ¼ 6), and PO (–A–, n ¼ 6) administrations of SLP
(1 mg/kg) in jennies. Bars represent standard deviation of the mean.
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Sulpiride administrations at 1 mg/kg via IV, IM, and PO
routes were well tolerated. This dose was chosen according
to recent studies assessing the effectiveness of SLP when
administered daily for a 21-day period [9,10] and the PK
proﬁle after a single-dose administration in horses [12]. No
adverse effects were observed during the present study.
The mean concentration versus time curves of the three
treatments are reported in Fig. 1.3.1. IV Administration
After IV administration, all concentration versus time
curves were analyzed systematically using the extended
least squares regression analysis, according to a mono-
compartment or a two-compartment body model. Statis-
tical analysis of the ﬁt of model to the curves indicated that
the data sets were consistent with a two-compartment
body model. Monocompartment model was also able toTable 2
Main (monocompartment model) pharmacokinetic parame-
ters of sulpiride (SLP) after intramuscular (IM) administration
of SLP (1 mg/kg) in a jenny.
Parameters IM (n ¼ 1)
R2 0.97
AUC0–N (ng hr/mL) 4,040.21
K01 (1/hr) 16.25
K10 (1/hr) 0.32
HL alpha (hr) 0.04
HL beta (hr) 2.16
CL (mL/hr/kg) 247.51
VD (mL/kg) 771.41
Tmax (hr) 0.25
Cmax (ng/mL) 1,197.79
F% 75.21
Abbreviations: AUC0–N, area under the plasma concentra-
tion–time curve extrapolated to inﬁnity; CL, clearance; Cmax,
peak plasma concentration; F%, absolute bioavailability; HL
alpha, distribution half-life; HL beta, disposition half-life; K01,
absorption rate constant; K10, elimination rate constant; R2,
correlation coefﬁcient; Tmax, time of peak; VD, volume of
distribution.ﬁt the curves in three cases of the six, but the Akaike co-
efﬁcient was greater than that in the two-compartment
body model ﬁtting. Sulpiride was detectable up to 8, 10,
and 24 hours in one, four, and one subject, respectively, and
had dropped below the LOD of the method at 34 hours.
Distribution in peripheral tissues was rapid (K12 ¼ 1.78 1/
hr), with a transfer rate constant from tissue to plasma (K21)
that was almost half the elimination rate constant (K10).
The average half-life of elimination was 4.24 hours; the CL
and VD were fast and wide, respectively. The full PK pa-
rameters are reported in Table 1.
3.2. IM Administration
After IM administration, data were consistent with a
two-compartment body model for ﬁve subjects. Data set
from one animal was consistent with a monocompartment
body model (Table 2). The plasma concentrations of SLP
were detectable from 5 minutes to 10 hours in all the ani-
mals. Sulpiride showed a short Tmax (0.32 hours) and fast
distribution half-life (0.40 hours) for the two-
compartmental model, whereas these latter values were
shorter (0.04 hours) in themonocompartment data set. The
Cmax values were quite similar within the range 1,197–
1,534 ng/mL. The average value for F% after IM adminis-
tration was 73.5  7.2. The average CL value was greater
than that found after IV administration, but if corrected for
the F%, the difference was no longer signiﬁcant (P ¼ .56).
The mean half-life of elimination was 3.87 hours. The
transfer rate constant from tissue to plasma (K21) was
similar to the rate of distribution in peripheral tissues (K12).
The full PK parameters are reported in Table 1.
3.3. PO Administration
After PO administration, large variability in plasma
concentrations was found among the subjects. The plasma
concentrations of SLP were detectable from 15 (n ¼ 4), 30
(n ¼ 1), or 45 minutes (n ¼ 1) to 2 (n ¼ 1), 4 (n ¼ 2), or 8
hours (n ¼ 4). A two-compartment open-model ﬁrst-order
absorption was the best ﬁt for four data sets. Two data sets
were not possible to be ﬁt with any compartmental anal-
ysis. A noncompartmental analysis was also impossible
because the elimination part of the curve got less than
three points. The plasma concentrations of the drug were
lower (P< .05) than those at the corresponding time points
for the other routes of administration. In addition, drug
absorption was slowest for the PO route (P < .01), with a
Tmax of 1.37 hours. AUC0–Nwas small and consequently the
PO F% was 9.4  5.9. These ﬁndings should be considered
with the caveat that because of their large variability, they
have limited value for predicting clinical behavior. A larger
sample size of animals is warranted. The full PK parameters
are reported in Table 1.
4. Discussion
Several studies have been conducted in humans after IV,
IM, and PO administrations of SLP [15–18]. The clinical dose
administered to humans [1] is greater than the dose used in
equine species because the desired effect is different (treat
M. Giorgi et al. / Journal of Equine Veterinary Science xx (2014) 1–6 5mental disorder vs. stimulate ovulation and/or lactation)
and for allometric reasons [19]. The lack of adverse effects
in jennies given 1 mg/kg concurs with a previous study in
nurse mares [12] and with the good tolerance previously
reported in human beings [5]. This also supports clinical
reports showing no adverse effects in horses after a 3-week
treatment period with this dose regimen [10]. Of relevance
however, is the fact that SLP probably does not bind to
plasma proteins [20], and it is likely to be predominantly
excreted by the kidneys, mainly by glomerular ﬁltration
[15]. Hence, precautions should be taken in patients with
impaired renal function, where the elimination half-life
could be prolonged, whereas the cumulative amount
excreted in the urine and the total and the renal clearances
would be reduced [21]. This should be considered of
particular importance in donkeys where the SLP CL has
been found to be greater than that reported in horses [12].
It is important to note that SLP does not bind to red
blood cells [17]. This might mean that the plasma concen-
tration of SLP directly reﬂects the magnitude of clinical
responses. Hence, SLP can be directly assayed in plasma for
drug monitoring or dosage regimen optimization.
After IV and IM administrations, data sets were mainly
consistent with a two-compartment model. This concurs
with some previous horse [12] and human studies [17];
however, it is in disagreement with others [16]. The HL
beta value was not statistically different between IV and
IM administrations, a ﬁnding supported by horse [12] and
human [16,17] data. The IM F% was 73.5%; this is not in
line with some previous data in horses where bioequiv-
alence between IV and IM administrations was reported
[12]. This ﬁt with the well-documented PK differences
between donkeys and horses [22]. The donkey therefore
should not be regarded as a small odd-looking horse but
should be recognized and treated as a species in its own
right.
After PO administration, SLP absorption was relatively
slow, with very large variations among individuals in the
rate and the extent of absorption. These phenomena have
been previously reported in horses [12]. The PO F% of SLP
is quite low in both humans (approximately 35%) [18]
and horses (20.4%) [12], and the PO F% reported in this
study was even lower. The low PO F% in equids compared
with that in humans could be the result of physico-
chemical features of SLP. Indeed, considering that SLP is a
weak base, existing in the ionized form at gastric and
physiological pH, it is unsurprising that it is poorly
absorbable, especially in horses whose environmental pH
is relatively acidic. However, the overnight fasting could
have negatively affected the drug absorption, causing
dramatic reduction in the gastric pH compared with fed
animals.
Many physiological features of donkeys are different
from those of horses. For example, plasma volume is
maintained in dehydrated donkeys even when they lose
20% of normal body water, whereas horses are, by far, less
resistant to this challenge [23]. Donkeys also appear to
possess an increased metabolic capacity for certain drugs,
which may be related to differences in cytochrome P450
isoenzymes [24]. Some of these differences might explain
the dissimilarity in PO F%. In addition, some recent studieshave conﬁrmed that the IM and PO F% of drugs may vary
drastically between horses [25] and donkeys [26].
Clearance after IV and IM administrations was 133.81
and 165.77 mL/hr/kg, respectively; these are greater than
the reported value for horses [12]. The greater CL in donkey
compared with horses has also been previously proven
[25,26].
An earlier metabolic study reported four different
metabolic reactions of SLP in the liver; these vary in
importance for different animal species [27]. However, the
unmetabolized drugwas found to be predominant in all the
tested species (with about 90% of an IV dose recovered
unchanged in the urine [17]), indicating not only that a
limited role in reducing the systemic availability of SLP can
be attributed to the liver but also and of greater importance
that the pharmacologic properties of SLP can be essentially
attributed to the unchanged agent [27]. If a similar
metabolic pattern is assumed for donkeys, it might be
hypothesized that SLP will not accumulate substantially
when given at 1 mg/kg/d for several days of therapy.
Indeed, the plasma concentration after 10 hours is
very close to the LOQ, and SLP is known to not
affect (inhibit) the metabolism [27]. A recent study has
successfully proposed an in situ forming gel-like depot of a
polyaspartamide–polylactide copolymer for once a week
administration of SLP in rabbits [28]. If this gel also proved
to have application in equine species, it would offer a
number of potential advantages. First, it could ensure that
the titration schedule is simpler and easier to manage
because of the reduction in dosing frequency (once aweek),
with better tolerance and increased compliance for both
owners and animals. Second, the likelihood of adverse ef-
fects due to abrupt peaks in plasma concentrations and lack
of effectiveness (due to rapidly decreasing post-peak
plasma concentrations) is reduced because of the unifor-
mity of SLP plasma concentrations. Further speciﬁc studies
are needed to clarify this issue.5. Conclusions
In the present study, IM and IV administrations have
been shown to be similar but not bioequivalent. These
routes are deﬁnitely preferable to PO dosing because of its
very low F%. Although a single daily administration at 1mg/
kg is used in clinical practice, a sustained release formula-
tion would be preferred to considerably reduce the labor,
and from the PK point of view, avoid the abrupt high peaks
in plasma concentrations, giving a better uniformity to SLP
plasma concentrations.Acknowledgments
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